Curriculum vitae
CV
Education, experience, research, publications, and technical skills.
Professional Summary
| Full Name | Zack (Zehua) Wang |
| Current Role | PhD Candidate in Pharmacology, University of Auckland |
| Field | Pharmacometrics, clinical trial simulation, and model-informed dosing |
| Location | Auckland, New Zealand |
| zwan942@aucklanduni.ac.nz | |
| University Profile | profiles.auckland.ac.nz/zack-wang |
| linkedin.com/in/zack-wang-pmx | |
| Languages | English; Chinese (Mandarin); Chinese (Cantonese) |
Experience
-
Aug 2026-Present Academic Casual
University of Auckland, Faculty of Medical and Health Sciences - Supports academic activities within the Faculty of Medical and Health Sciences.
-
Dec 2025-Jul 2026 Professional Casual
University of Auckland, Department of Pharmacology and Clinical Pharmacology - Supported academic, research, and operational activities, including developing R Shiny applications and virtual simulation exercises for MEDSCI 318.
Education
-
2025-Present Doctoral Candidate in Pharmacology and Clinical Pharmacology
University of Auckland, Faculty of Medical and Health Sciences, School of Medicine - Doctoral research: Advancing the Evidence for Model-Based Dosing in the Clinical Setting.
- Uses pharmacometrics, clinical trial simulation, and nonlinear mixed-effects modelling to study dose selection, treatment effects, and disease progression.
-
2022-2025 Master of Science
China Pharmaceutical University, Nanjing, China - Research in pharmacokinetics, PBPK/PD modelling, drug disposition, and translational pharmacology.
- First author of a PBPK-PD model of topoisomerase inhibitor antibody-drug conjugates published in European Journal of Pharmaceutical Sciences.
-
2018-2022 Bachelor of Engineering
Shandong First Medical University, Jinan, China - Training in pharmaceutical engineering, laboratory methods, formulation-related research, and data analysis.
Selected Research
-
2025-Present Model-informed dosing and target concentration intervention
University of Auckland - Uses clinical trial simulation and population PK/PD modelling to evaluate dosing and sampling strategies for high-risk medicines.
- Current work includes vancomycin AUC-guided dosing and Bayesian dose prediction in infectious diseases.
-
2025-Present Disease progression modelling in Alzheimer's disease
University of Auckland - Uses longitudinal models to quantify disease progression and treatment effects while keeping estimands, time windows, and uncertainty explicit.
-
2022-2025 PBPK/PD modelling of antibody-drug conjugates
China Pharmaceutical University - Developed a translational PBPK-PD model to predict pharmacokinetics, tumour growth inhibition, and toxicity risks of topoisomerase inhibitor antibody-drug conjugates in mice and humans.
- Contributed to PBPK and transporter-mediated drug-disposition analyses across SPT-07A and liver-injury models.
Selected Publications
- Wang Z, Zhu J, Sang L, Tang L, Zhang S, Tan Y, Zhao Y, Hao K. PBPK-PD model for predicting pharmacokinetics, tumor growth inhibition, and toxicity risks of topoisomerase inhibitor ADCs in mice and humans. European Journal of Pharmaceutical Sciences. 2025;213:107234. doi:10.1016/j.ejps.2025.107234.
- Zhu X, Kong W, Wang Z, Liu X, Liu L. Prediction of SPT-07A Pharmacokinetics in Rats, Dogs, and Humans Using a Physiologically-Based Pharmacokinetic Model and In Vitro Data. Pharmaceutics. 2024;16(12):1596. doi:10.3390/pharmaceutics16121596.
- Zhi H, Zhongyan Wang, Zhu X, Wu W, Yang L, Dai Y, Zehua Wang, Jiang L, et al. Chronic liver injury decreases levels of cerebral carnitine and acetylcarnitine in rats partly due to the downregulation of organic cation transporters OCT1/2 and OCTN2 at the blood-brain barrier. Drug Metabolism and Disposition. 2025;53(5):100072. doi:10.1016/j.dmd.2025.100072.
- Zhi H, Dai Y, Su L, Yang L, Wu W, Zehua Wang, Zhu X, Liu L. Thioacetamide-Induced Acute Liver Injury Increases Metformin Plasma Exposure by Downregulating Renal OCT2 and MATE1 Expression and Function. Biomedicines. 2023;11(12):3314. doi:10.3390/biomedicines11123314.
Technical Capabilities
-
Pharmacometrics and clinical pharmacology
- Population PK and PK/PD modelling; exposure-response and disease-progression modelling.
- Clinical trial simulation, model-informed dosing, optimal sampling, and scenario analysis.
- Model evaluation with diagnostic plots, simulation-based checks, sensitivity analyses, and traceable assumptions.
-
Software and reproducible workflows
- NONMEM, R, Phoenix WinNonlin, Python, Wings for NONMEM, Monolix, PK-Sim, and Berkeley Madonna.
- R Markdown or Quarto-style reporting, Git-based version control, and automated tables and figures.
-
Biomedical and translational methods
- PBPK/PD modelling, in vitro-in vivo extrapolation, transporter-mediated disposition, HPLC-MS, qPCR, and Western blotting.
Honours and Service
-
2026 - Judging and Prizing Committee Co-Lead, HealtheX 2026, Faculty of Medical and Health Sciences.
-
2025 - Outstanding Graduate, China Pharmaceutical University.
-
2024 - Exploring the World Scholarship for International Research.
- Excellent Poster, 14th National Drug Metabolism Conference.
-
2022 - Outstanding Graduate, Shandong First Medical University.
Research Interests
-
Model-informed dosing
- Evidence for dosing and sampling decisions in routine care.
- Bayesian dose individualisation and implementation of model-based dosing tools.
-
Pharmacometrics and clinical pharmacology
- Population PK/PD, exposure-response, disease progression, and clinical trial simulation.
- Transparent reporting for clinical, regulatory, and policy-facing audiences.
-
Translational pharmacology
- PBPK/PD modelling, cross-species extrapolation, and transporter-mediated drug disposition.